NCT06676527 Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma
| NCT ID | NCT06676527 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jinling Hospital, China |
| Condition | Neoplasms |
| Study Type | OBSERVATIONAL |
| Enrollment | 39 participants |
| Start Date | 2024-09-01 |
| Primary Completion | 2026-09-01 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This is a multicenter real world study (RWS) initiated by the investigator. Eligible patients will be selected for treatment with second-line treatment including vorolanib and followed up. The real survival data of patients after medication will be collected and compared with the data of CONCEPT study, and multi-factor stratified analysis of the efficacy of voronib will be conducted.
Eligibility Criteria
Inclusion Criteria: * Subjects have fully understood and voluntarily signed the informed consent form (ICF); * 18-80 years old (at the time of signing the informed consent); Both men and women; ECOG PS score: 0-1; * Renal cell carcinoma with clear cell components confirmed histologically or cytopathologically, including unresectable or recurrent metastatic renal cell carcinoma dominated by clear cell components; * According to RECIST (version 1.1), there are targets that are considered to be observable; * The main organs function well. Exclusion Criteria: * A history of malignancies other than the disease studied within the past 5 years, other than malignancies that are expected to be cured with treatment (including but not limited to adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or breast ductal carcinoma in situ treated with radical surgery); * Systemic treatment with other antitumor agents, including targeted agents, immunotherapy